Coherus BioSciences
333 Twin Dolphin Dr, #600
Redwood City
CA
94065
United States
Tel: 800-794-5434
Website: https://www.coherus.com/
About Coherus BioSciences
We are committed to making high-value biosimilars affordable for everyone. It’s an unconventional approach to business that defines who we are and what we do.
At Coherus, we hold ourselves to a higher standard. We don’t break the rules—we write our own.
In early 2021, we expanded our mission into immuno-oncology with a collaboration with Shanghai Junshi Biosciences for the development and commercialization of toripalimab, Junshi Biosciences’ novel anti-PD-1 antibody, in the United States and Canada.
We are embarking on a new phase in our evolution, focused on expanding patient access to important, cost-effective medicines and delivering significant savings to the U.S. healthcare system. Join us, as we seek to break down barriers and make a difference in patients’ lives.
Stock Symbol: CHRS
Stock Exchange: NASDAQ
192 articles with Coherus BioSciences
-
Coherus Biosciences Appoints Mary Szela To Board of Directors
9/25/2014
-
Coherus Biosciences' Biosimilar Meets Primary Endpoint In Pivotal Pharmacokinetic Clinical Study
8/15/2014
-
Coherus Biosciences Announces Initiation Of Phase 3 Trial Of CHS-0214 (Investigational Etanercept Biosimilar) In Chronic Plaque Psoriasis (RaPsOdy)
7/16/2014
-
Coherus Biosciences Appoints Dr. V. Bryan Lawlis, Jr. To Board Of Directors
7/9/2014
-
Coherus Biosciences Announces Initiation Of Phase 3 Trial Of Chs-0214 (Investigational Etanercept Biosimilar) In Rheumatoid Arthritis
6/23/2014
-
Coherus Biosciences Appoints Vince R. Anicetti As Senior Vice President, Global Quality
6/9/2014
-
Redwood City's Coherus Biosciences Locks In $55 Million Series C
5/20/2014
-
Coherus Biosciences Appoints Lisa M. Bell, Ph.D., Senior Vice President, Global Regulatory Affairs
5/12/2014
-
Coherus Biosciences Appoints Michael A. Fleming As Senior Vice President, Commercial Strategy
4/28/2014
-
Coherus Biosciences Invited To Present At 2014 J.P. Morgan Annual Healthcare Conference
1/7/2014
-
Coherus Biosciences Announces CHS-0214 (Proposed Etanercept Biosimilar) Meets Primary Endpoint In Pivotal Pharmacokinetic Clinical Study
10/28/2013
-
Baxter International, Inc. and Coherus Biosciences Sign $246 Million Biosimilars Pact
9/3/2013